Neonatal alloimmune thrombocytopenia complicated by maternal autoimmune thrombocytopenia
Neonatal alloimmune thrombocytopenia should be suspected in any thrombocytopenic infant born to a healthy non-thrombocytopenic mother. Nevertheless, the condition occurs in only 1 or 2/10 000 births.' More often transient neonatal immune thrombocytopenia results from maternal idiopathic thrombocytopenic purpura.
We report the coexistence of alloimmunisation and autoimmunisation against platelets in a mother who delivered two infants with transient thrombocytopenia. Such a case has not been described before. Detailed serological analysis was facilitated by the platelet suspension immunofluorescence test. This test is based on the observation that aspecific fluorescence can be prevented by fixing the platelets with paraformaldehyde.2
Case report
An infant was born to a primigravida after an uneventful pregnancy. Six hours after delivery he showed generalised petechiae. His platelet count was 53 x 109/l and fell to 12 x 109/1 after 24 hours. There was no history of a bleeding tendency in the mother, whose platelet count was 400 x 109/l.
Because alloimmunisation was assumed, a platelet concentrate prepared from the mother's blood was given on the fourth day of life. Immediately after transfusion his platelet count rose to 85 x 109/1 and was normal within 10 days (figure). With the platelet suspension immunofluorescence test we detected IgGplatelet alloantibodies of anti-Zwa specificity in the mother's serum. Platelet typing showed her to be homozygous Zwb, and the child Zwa Zwb. Unexpectedly, we found a weakly positive reaction of maternal platelets after incubation with her own serum, suggesting that weak autoantibodies against platelets were also present. An eluate from her platelets did not react with donor platelets..
In the 28th week of her second pregnancy we again detected plateletspecific alloantibodies in her serum. Her platelet count was 90 x 109/1.
Result of a direct platelet suspension immunofluorescence test was apparently positive for anti-IgM. An ether eluate from her platelets reacted strongly with donor platelets. Thus transfusion of maternal platelets to the child was contraindicated. In the 39th week labour was induced. Within one minute after delivery the baby developed generalised petechiae. The platelet count in the cord blood was 25 x 10911. Transfusion of a platelet concentrate prepared from the blood of a Zw(a-b +) donor increased the platelet count to 140 x 109/l. Over the next eight days the count gradually fell to 40 x 109/1 and then rose to normal (figure).
Comment
Generally the most effective treatment for neonatal alloimmune thrombocytopenia is transfusion of maternal platelets.3 Often the specificity of the platelet antibodies is unknown when transfusion is needed, and the maternal platelets lack the antigen responsible for alloimmunisation. The platelet antigen most commonly associated with the condition is PlAl or Zwa.l The chance that platelets from a random donor will be compatible is negligible, since the prevalence of Zwa in the normal population is 97-6%. Only a few blood banks type for platelet antigens; thus the mother is the most obvious donor for all her affected infants. In our patient, however, a smouldering autoimmune thrombocytopenia became clear. Transfusion of her platelets was therefore contraindicated and platelets from a Zw(a -b +) donor were used.
Autoimmune thrombocytopenia is usually caused by IgG antibodies4 that cross the placenta.5 Platelet autoantibodies are often aspecific (unpublished results). Transfusions of platelet concentrates from random donors are therefore of little value in these cases. The platelets will be immediately sensitised with the maternal IgG autoantibodies present in the infant and subsequently destroyed. In our case, however, the autoantibodies in the maternal blood were of the IgM class. This explains why the donor platelets were effective in the baby: IgM antibodies do not cross the placenta. 
